New stock news | Iflytek Medical Hong Kong Stock IPO and domestic unlisted shares "fully circulating" approved by the China Securities Regulatory Commission.

On July 19, the China Securities Regulatory Commission issued a filing notice regarding the overseas issuance and listing of shares by iFlytek Medical Technology Co., Ltd. and the "full circulation" of domestically unlisted shares. It is reported that the company plans to issue no more than 23,103,350 shares of ordinary shares for overseas listing and listing on the Hong Kong Stock Exchange. In addition, 14 shareholders of the company intend to convert a total of 70,261,562 domestically unlisted shares into overseas listed shares, which will also be listed on the Hong Kong Stock Exchange. The prospectus shows that iFlytek Medical is a global leader in the medical artificial intelligence industry, and is also a pioneer in the commercialization of large-scale solutions for medical artificial intelligence in China. The company is committed to building a new type of diagnosis and treatment system that combines man and machine, and supports medical reforms in China. According to Frost & Sullivan data, iFlytek Medical ranks first in terms of revenue scale in the Chinese medical artificial intelligence industry in 2022. iFlytek Medical has paved the way in advancing and implementing large-scale language models in the domestic medical industry, utilizing deep learning technology to continuously understand, summarize, generate, and predict new content through training on large datasets. The company's proprietary iFlytek Xinghuo Medical large model is applied in over 300 medical scenarios. According to a test conducted by the China National Science and Technology Information Resource Comprehensive Utilization and Public Service Center, iFlytek Xinghuo Medical large model surpasses GPT in six dimensions of natural language processing tasks in medical scenarios including expert-level medical knowledge map Q&A, clinical language understanding, medical document generation, disease diagnosis and treatment recommendations, multi-turn medical dialogue, and multi-modal interaction. As an active participant in China's healthcare reform, iFlytek Medical is able to continuously meet the changing demands of the medical industry and expand its diverse user base. As of January 19th, iFlytek Medical has provided products and services to around 52,000 primary healthcare institutions, covering over 400 counties in more than 30 provinces, as well as over 400 hospitals (including more than 40 of China's top 100 hospitals and 7 of its top 10 hospitals). According to Frost & Sullivan, the company's hearing aids ranked first in terms of sales at the annual "618 Shopping Festival" on China's two major e-commerce platforms JD.com and Tmall in 2023, and its post-diagnosis management platform has served over 48,000 patients. Furthermore, according to Frost & Sullivan data, as of January 19th, iFlytek Medical's Intelligent Medical Assistant is the world's first and only intelligent solution to pass the national physician qualification examination (comprehensive written examination). In terms of revenue, it ranked first in the clinical decision support system market for primary healthcare institutions in China in 2022, with a market share of 76.6%.